NDAINJECTIONINJECTABLE
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
ARGATROBAN (argatroban) by Fresenius Kabi is thrombin inhibitors [moa]. Approved for heparin-induced thrombocytopenia, thrombosis, coronary artery bypass graft surgery. First approved in 2015.
Drug data last refreshed Yesterday
Mechanism of Action
Thrombin Inhibitors
Pharmacologic Class:
Anti-coagulant
Indications (3)
Worked on ARGATROBAN at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.